Completion of the divestment of Aspen's Nutritionals business to Lactalis
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) ("Aspen Holdings")
Registration number: 1985/0002935/06
Share code: APN
and its subsidiaries (collectively "Aspen" or "the Group")
COMPLETION OF THE DIVESTMENT OF ASPEN'S NUTRITIONALS BUSINESS TO LACTALIS
With reference to previous announcements to shareholders in respect of this transaction, Aspen is pleased
to confirm that it completed the divestment of its Nutritionals Business to the Lactalis Group for a gross
consideration of EUR 740 million on 31 May 2019. Aspen can also confirm that it has received proof of
payment of the gross consideration from the Lactalis Group and expects all of the funds to be in its bank
accounts within the next few days. The estimated net cash inflows from the transaction, after payment of
transaction related taxes, the buy-out of minority shareholders and the payment of transaction costs, will
be approximately EUR 635 million and the financial effects remain in line with Aspen's expectations.
The completion of this divestment and the divestment of a portfolio of products in Australia to Mylan,
announced on 20 May 2019, are important steps towards achieving one of Aspen's stated priorities, namely
the deleveraging of its balance sheet.
3 June 2019
Investec Bank Limited
Date: 03/06/2019 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.